Trial Profile
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Nivolumab (Primary) ; Osimertinib (Primary) ; Telisotuzumab vedotin (Primary)
- Indications Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AbbVie
- 26 Jun 2023 Planned End Date changed from 8 Dec 2023 to 24 Apr 2024.
- 26 Jun 2023 Planned primary completion date changed from 8 Dec 2023 to 24 Apr 2024.
- 21 Jun 2023 Status changed from recruiting to active, no longer recruiting.